论文部分内容阅读
本研究探讨氨磷汀(amifostine,AMF)对骨髓增生异常综合征(MDS)患者的疗效及副作用。采用单用AMF或联合红细胞生成素(rhEPO)治疗12例MDS患者,其中8位高龄患者采用AMF联合rhEPO治疗,4例单用AMF治疗。治疗方案为AMF0.4g静脉滴注,5天为1疗程,休息2天,连续3疗程为1个治疗周期;rhEPO6000U,皮下注射,1周3次。结果显示:12例MDS患者的血液学指标均有改善,显效11例(91.7%),微效1例(8.3%),其中血红蛋白有效率为100%,白细胞有效率为75%,血小板有效率为58.3%。2例长期依靠输血的患者在氨磷汀治疗后输血间隔逐渐延长,输血量明显减少。AMF的副作用主要表现为胃肠道反应,但所有患者均可耐受。结论:氨磷汀是骨髓增生异常综合征治疗中一种较有潜力的药物,对同时伴有多器官基础疾病的高龄患者更是一种安全、有效的药物,其疗效随维持时间的延长而显著提高。
This study was to investigate the efficacy and side effects of amifostine (AMF) in patients with myelodysplastic syndrome (MDS). Twelve MDS patients were treated with AMF alone or combined with rhEPO (rhEPO). Eight of the elderly patients were treated with AMF plus rhEPO and four with AMF alone. Treatment regimen AMF0.4g intravenous drip, 5 days for a course of treatment, rest for 2 days, 3 consecutive courses of treatment for a treatment cycle; rhEPO6000U, subcutaneous injection, 1 week 3 times. The results showed that the hematological indexes of 12 patients with MDS were improved in 11 cases (91.7%) and 1 case (8.3%), the effective rate of hemoglobin was 100%, leukocyte efficiency was 75%, platelet effective rate For 58.3%. Two patients with long-term transfusion-dependent transfusion intervals were gradually prolonged after amifostine treatment, and blood transfusion volume was significantly reduced. Side effects of AMF are mainly gastrointestinal reactions, but all patients are tolerated. Conclusion: Amifostine is a potential drug in the treatment of myelodysplastic syndromes. It is a safe and effective drug for elderly patients with multiple organ-based diseases. The efficacy of amifostine increases with the prolongation of maintenance time Significantly increased.